[S02DA03, antipyrine, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Mannitol.]
[J01GA01, streptomycin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Streptomycin.]
[M03AB01, succinylcholine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Mannitol.]
[A02BX02, sucralfate, Mannitol may increase the excretion rate of Sucralfate which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CG01, sulbactam, Mannitol may increase the excretion rate of Sulbactam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01EC02, sulfadiazine, Mannitol may increase the excretion rate of Sulfadiazine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01EC01, sulfamethoxazole, Mannitol may increase the excretion rate of Sulfamethoxazole which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AB02, sulindac, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Sulindac.]
[M01AX04, apazone, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Azapropazone.]
[L02BA01, tamoxifen, The serum concentration of Mannitol can be increased when it is combined with Tamoxifen.]
[N05CD07, temazepam, Mannitol may increase the excretion rate of Temazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC03, terbutaline, Mannitol may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AE07, dabigatran etexilate, Mannitol may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.]
[G03BA03, testosterone, Mannitol may increase the excretion rate of Testosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[S03AA02, tetracycline, Mannitol may increase the excretion rate of Tetracycline which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DI02, ceftaroline fosamil, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Ceftaroline fosamil.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Mannitol.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Mannitol is combined with Thalidomide.]
[R03DA07, theobromine, The risk or severity of adverse effects can be increased when Theobromine is combined with Mannitol.]
[P02CA02, thiabendazole, Mannitol may increase the excretion rate of Thiabendazole which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AD03, thiethylperazine, Mannitol may increase the excretion rate of Thiethylperazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Mannitol.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Thioridazine is combined with Mannitol.]
[G04BE06, moxisylyte, Mannitol may increase the excretion rate of Moxisylyte which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL03, tiapride, Mannitol may increase the excretion rate of Tiapride which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC05, ticlopidine, Mannitol may increase the excretion rate of Ticlopidine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX01, tilidine, The therapeutic efficacy of Mannitol can be decreased when used in combination with Tilidine.]
[S01ED01, timolol, Mannitol may increase the excretion rate of Timolol which could result in a lower serum level and potentially a reduction in efficacy.]
[P01AB02, tinidazole, Mannitol may increase the excretion rate of Tinidazole which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA12, tobramycin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Tobramycin.]
[A10BB05, tolazamide, Mannitol may increase the excretion rate of Tolazamide which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AX02, tolazoline, The risk or severity of adverse effects can be increased when Mannitol is combined with Tolazoline.]
[V04CA01, tolbutamide, Mannitol may increase the excretion rate of Tolbutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA21, tolmetin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Tolmetin.]
[N02AX02, tramadol, Mannitol may increase the excretion rate of Tramadol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the orthostatic hypotensive activities of Mannitol.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Mannitol is combined with Tretinoin.]
[C03DB02, triamterene, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Triamterene.]
[N05CD05, triazolam, Mannitol may increase the excretion rate of Triazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA06, trichlormethiazide, The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Mannitol.]
[A16AX12, trientine, Mannitol may increase the excretion rate of Triethylenetetramine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AD02, trifluridine, Mannitol may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AA05, trimebutine, Mannitol may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AC02, trimethadione, The risk or severity of hyperkalemia can be increased when Trimethadione is combined with Mannitol.]
[C02BA01, trimethaphan, Mannitol may increase the hypotensive activities of Trimethaphan.]
[J01EA01, trimethoprim, Mannitol may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA06, trimipramine, The serum concentration of Trimipramine can be increased when it is combined with Mannitol.]
[C09CA09, azilsartan medoxomil, The risk or severity of adverse effects can be increased when Mannitol is combined with Azilsartan medoxomil.]
[R03DX07, roflumilast, Mannitol may increase the excretion rate of Roflumilast which could result in a lower serum level and potentially a reduction in efficacy.]
[L01FX04, ipilimumab, Mannitol may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX04, vandetanib, The serum concentration of Mannitol can be increased when it is combined with Vandetanib.]
[R02AA14, oxyquinoline, Mannitol may increase the excretion rate of Oxyquinoline which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH05, linagliptin, The serum concentration of Mannitol can be increased when it is combined with Linagliptin.]
[J05AP02, telaprevir, The serum concentration of Mannitol can be increased when it is combined with Telaprevir.]
[S01AA28, vancomycin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Vancomycin.]
[N03AX21, ezogabine, Mannitol may increase the excretion rate of Ezogabine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AF01, rivaroxaban, Mannitol may increase the excretion rate of Rivaroxaban which could result in a lower serum level and potentially a reduction in efficacy.]
[R03AC18, indacaterol, The serum concentration of Indacaterol can be increased when it is combined with Mannitol.]
[B01AC24, ticagrelor, The serum concentration of Mannitol can be increased when it is combined with Ticagrelor.]
[C08DA01, verapamil, The serum concentration of Mannitol can be increased when it is combined with Verapamil.]
[N06AX09, viloxazine, Mannitol may increase the excretion rate of Viloxazine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CA01, vinblastine, The serum concentration of Vinblastine can be increased when it is combined with Mannitol.]
[C04AX07, vincamine, Mannitol may increase the hypotensive activities of Vincamine.]
[L01CA02, vincristine, The serum concentration of Vincristine can be increased when it is combined with Mannitol.]
[B03BA01, vitamin B12, Mannitol may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA03, warfarin, Mannitol may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[C03BA10, xipamide, The risk or severity of adverse effects can be increased when Xipamide is combined with Mannitol.]
[L01EC01, vemurafenib, The serum concentration of Mannitol can be increased when it is combined with Vemurafenib.]
[M05BA03, pamidronic acid, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Pamidronic acid.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Mannitol.]
[M05BA05, tiludronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Mannitol is combined with Tiludronic acid.]
[B06AC02, icatibant, Mannitol may increase the excretion rate of Icatibant which could result in a lower serum level and potentially a reduction in efficacy.]
[L01ED01, crizotinib, The serum concentration of Mannitol can be increased when it is combined with Crizotinib.]
[A02BC04, rabeprazole, Mannitol may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[M05BA06, ibandronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Mannitol is combined with Ibandronate.]
[G03AC10, drospirenone, The risk or severity of adverse effects can be increased when Drospirenone is combined with Mannitol.]
[V03AC02, deferiprone, Mannitol may increase the excretion rate of Deferiprone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the excretion rate of Mannitol which could result in a higher serum level.]
[L01EJ01, ruxolitinib, Mannitol may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD07, tolterodine, Mannitol may increase the excretion rate of Tolterodine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DH04, doripenem, Mannitol may increase the excretion rate of Doripenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB03, atenolol, The risk or severity of adverse effects can be increased when Atenolol is combined with Mannitol.]
[M01CB03, auranofin, Mannitol may increase the excretion rate of Auranofin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Mannitol.]
[R07AX02, ivacaftor, The serum concentration of Mannitol can be increased when it is combined with Ivacaftor.]
[B03XA04, peginesatide, Mannitol may increase the excretion rate of Peginesatide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC07, azacitidine, Mannitol may increase the excretion rate of Azacitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX01, azathioprine, Mannitol may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC05, gemcitabine, Mannitol may increase the excretion rate of Gemcitabine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DF01, aztreonam, Mannitol may increase the excretion rate of Aztreonam which could result in a lower serum level and potentially a reduction in efficacy.]
[R02AB04, bacitracin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Bacitracin.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Mannitol.]
[M03BX01, baclofen, Mannitol may decrease the excretion rate of Baclofen which could result in a higher serum level.]
[A08AA11, lorcaserin, Mannitol may increase the excretion rate of Lorcaserin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD12, mirabegron, The serum concentration of Mannitol can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The serum concentration of Mannitol can be increased when it is combined with Carfilzomib.]
[V03AX03, cobicistat, The serum concentration of Mannitol can be increased when it is combined with Cobicistat.]
[L02BB04, enzalutamide, Mannitol may increase the excretion rate of Enzalutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX04, linaclotide, The risk or severity of adverse effects can be increased when Mannitol is combined with Linaclotide.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Mannitol.]
[L01EX05, regorafenib, The serum concentration of Mannitol can be increased when it is combined with Regorafenib.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Mannitol.]
[D02BA02, octinoxate, Mannitol may increase the excretion rate of Octinoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Mannitol.]
[N04BD02, rasagiline, Rasagiline may increase the orthostatic hypotensive activities of Mannitol.]
[C08CA13, lercanidipine, The risk or severity of adverse effects can be increased when Lercanidipine is combined with Mannitol.]
[V09IX04, fluorodeoxyglucose F18, Mannitol may increase the excretion rate of Fludeoxyglucose (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE03, sildenafil, The serum concentration of Mannitol can be increased when it is combined with Sildenafil.]
[V08CA11, gadofosveset, Mannitol may increase the excretion rate of Gadofosveset trisodium which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA05, ponatinib, The serum concentration of Mannitol can be increased when it is combined with Ponatinib.]
[B01AF02, apixaban, The serum concentration of Apixaban can be increased when it is combined with Mannitol.]
[A16AX08, teduglutide, Mannitol may increase the excretion rate of Teduglutide which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AX12, lomitapide, The serum concentration of Mannitol can be increased when it is combined with Lomitapide.]
[C04AX11, bencyclane, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Bencyclane.]
[A10BH04, alogliptin, Mannitol may increase the excretion rate of Alogliptin which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX09, glycerol phenylbutyrate, Mannitol may increase the excretion rate of Glycerol phenylbutyrate which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA01, bendroflumethiazide, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Mannitol.]
[L04AX06, pomalidomide, Mannitol may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA10, benorilate, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Benorilate.]
[A10BK02, canagliflozin, The serum concentration of Mannitol can be increased when it is combined with Canagliflozin.]
[A06AX06, tegaserod, The risk or severity of adverse effects can be increased when Mannitol is combined with Tegaserod.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Mannitol.]
[L03AA12, ancestim, Mannitol may increase the excretion rate of Ancestim which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH01, celecoxib, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Celecoxib.]
[L04AA18, everolimus, The serum concentration of Mannitol can be increased when it is combined with Everolimus.]
[N04AC01, benztropine, Mannitol may increase the excretion rate of Benzatropine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EC02, dabrafenib, The serum concentration of Dabrafenib can be increased when it is combined with Mannitol.]
[R02AX03, benzydamine, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Benzydamine.]
[L01EE01, trametinib, Mannitol may increase the excretion rate of Trametinib which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AX05, florbetapir F-18, Mannitol may increase the excretion rate of Florbetapir (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EB03, afatinib, The serum concentration of Mannitol can be increased when it is combined with Afatinib.]
[N06AX28, levomilnacipran, Mannitol may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AJ03, dolutegravir, The serum concentration of Dolutegravir can be increased when it is combined with Mannitol.]
[C08EA02, bepridil, The risk or severity of adverse effects can be increased when Mannitol is combined with Bepridil.]
[C02KX05, riociguat, The serum concentration of Riociguat can be increased when it is combined with Mannitol.]
[A10BJ03, lixisenatide, Mannitol may increase the excretion rate of Lixisenatide which could result in a lower serum level and potentially a reduction in efficacy.]
[C02KX04, macitentan, Mannitol may increase the excretion rate of Macitentan which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX26, vortioxetine, Mannitol may increase the excretion rate of Vortioxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[G03AC08, etonogestrel, Mannitol may increase the excretion rate of Etonogestrel which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AP05, simeprevir, The serum concentration of Mannitol can be increased when it is combined with Simeprevir.]
[J05AP08, sofosbuvir, Mannitol may increase the excretion rate of Sofosbuvir which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BK01, dapagliflozin, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Mannitol.]
[C01CA27, droxidopa, Mannitol may increase the excretion rate of Droxidopa which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB04, acebutolol, The risk or severity of adverse effects can be increased when Mannitol is combined with Acebutolol.]
[N05CH03, tasimelteon, Mannitol may increase the excretion rate of Tasimelteon which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA32, apremilast, Mannitol may increase the excretion rate of Apremilast which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BG02, formestane, Mannitol may increase the excretion rate of Formestane which could result in a lower serum level and potentially a reduction in efficacy.]
[S01ED02, betaxolol, The risk or severity of adverse effects can be increased when Betaxolol is combined with Mannitol.]
[V03AB34, fomepizole, Mannitol may increase the excretion rate of Fomepizole which could result in a lower serum level and potentially a reduction in efficacy.]
[C02CC01, bethanidine, Mannitol may increase the hypotensive activities of Bethanidine.]
[L01ED02, ceritinib, The serum concentration of Ceritinib can be increased when it is combined with Mannitol.]
[B01AC26, vorapaxar, The serum concentration of Mannitol can be increased when it is combined with Vorapaxar.]
[L01XH04, belinostat, The serum concentration of Belinostat can be increased when it is combined with Mannitol.]
[L01EM01, idelalisib, The serum concentration of Idelalisib can be increased when it is combined with Mannitol.]
[A10BK03, empagliflozin, Empagliflozin may increase the diuretic activities of Mannitol.]
[V08AA01, diatrizoic acid, Mannitol may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AA04, iothalamic acid, Mannitol may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CM19, suvorexant, The serum concentration of Mannitol can be increased when it is combined with Suvorexant.]
[A16AX10, eliglustat, The serum concentration of Mannitol can be increased when it is combined with Eliglustat.]
[S01AA15, dihydrostreptomycin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Dihydrostreptomycin.]
[A06AB04, phenolphthalein, The risk or severity of adverse effects can be increased when Mannitol is combined with Phenolphthalein.]
[A06AH03, naloxegol, The therapeutic efficacy of Mannitol can be decreased when used in combination with Naloxegol.]
[L01EX09, nintedanib, The serum concentration of Nintedanib can be increased when it is combined with Mannitol.]
[A06AG02, bisacodyl, The risk or severity of adverse effects can be increased when Mannitol is combined with Bisacodyl.]
[S03AA06, gentamicin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Gentamicin.]
[J05AP09, dasabuvir, The serum concentration of Dasabuvir can be increased when it is combined with Mannitol.]
[B01AF03, edoxaban, Mannitol may increase the excretion rate of Edoxaban which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EF01, palbociclib, The serum concentration of Mannitol can be increased when it is combined with Palbociclib.]
[L01EX08, lenvatinib, The serum concentration of Lenvatinib can be increased when it is combined with Mannitol.]
[L01XH03, panobinostat, The serum concentration of Panobinostat can be increased when it is combined with Mannitol.]
[J05AP07, daclatasvir, The serum concentration of Mannitol can be increased when it is combined with Daclatasvir.]
[N02BE01, acetaminophen, Mannitol may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DC01, bleomycin, Mannitol may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF08, adefovir dipivoxil, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Adefovir dipivoxil.]
[J05AP06, asunaprevir, The serum concentration of Mannitol can be increased when it is combined with Asunaprevir.]
[A07DA06, eluxadoline, The therapeutic efficacy of Mannitol can be decreased when used in combination with Eluxadoline.]
[A04AD14, rolapitant, The serum concentration of Mannitol can be increased when it is combined with Rolapitant.]
[G02CX02, flibanserin, The serum concentration of Mannitol can be increased when it is combined with Flibanserin.]
[A06AD03, magnesium peroxide, The risk or severity of adverse effects can be increased when Mannitol is combined with Magnesium peroxide.]
[M02AA25, aceclofenac, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Aceclofenac.]
[M01AB11, acemetacin, The therapeutic efficacy of Mannitol can be decreased when used in combination with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Mannitol.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Mannitol.]
[V03AB37, idarucizumab, Mannitol may increase the excretion rate of Idarucizumab which could result in a lower serum level and potentially a reduction in efficacy.]
[J02AC05, isavuconazole, The serum concentration of Mannitol can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Osimertinib can be increased when it is combined with Mannitol.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Mannitol.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Mannitol.]
[L01XG03, ixazomib, Mannitol may increase the excretion rate of Ixazomib which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC27, selexipag, The serum concentration of Selexipag can be increased when it is combined with Mannitol.]
[M04AB05, lesinurad, Mannitol may increase the excretion rate of Lesinurad which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AP10, elbasvir, The serum concentration of Elbasvir can be increased when it is combined with Mannitol.]
[J05AP11, grazoprevir, The serum concentration of Grazoprevir can be increased when it is combined with Mannitol.]
[M01AE16, alminoprofen, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Alminoprofen.]
[A02AB06, aloglutamol, The therapeutic efficacy of Mannitol can be decreased when used in combination with Aloglutamol.]
[N03AX23, brivaracetam, Mannitol may increase the excretion rate of Brivaracetam which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX52, venetoclax, The serum concentration of Mannitol can be increased when it is combined with Venetoclax.]
[N05BA08, bromazepam, Mannitol may increase the excretion rate of Bromazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Mannitol is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Mannitol may increase the excretion rate of Almasilate which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA01, amlodipine, The risk or severity of adverse effects can be increased when Amlodipine is combined with Mannitol.]
[C03CA02, bumetanide, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Bumetanide.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Mannitol.]
[C07AA19, bupranolol, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Bupranolol.]
[N07BC01, buprenorphine, The therapeutic efficacy of Mannitol can be decreased when used in combination with Buprenorphine.]
[N05BE01, buspirone, Mannitol may increase the excretion rate of Buspirone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX27, arsenic trioxide, The serum concentration of Mannitol can be increased when it is combined with Arsenic trioxide.]
[M02AA03, clofezone, Mannitol may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AF01, butorphanol, The therapeutic efficacy of Mannitol can be decreased when used in combination with Butorphanol.]
[A06AX07, plecanatide, The risk or severity of adverse effects can be increased when Mannitol is combined with Plecanatide.]
[A07EC04, balsalazide, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Balsalazide.]
[A06AH05, naldemedine, Mannitol may increase the excretion rate of Naldemedine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX16, deutetrabenazine, Mannitol may increase the excretion rate of Deutetrabenazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BF02, pregabalin, Mannitol may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA07, benazepril, The risk or severity of adverse effects can be increased when Benazepril is combined with Mannitol.]
[P01CA02, benznidazole, Mannitol may increase the excretion rate of Benznidazole which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XX08, linezolid, Linezolid may increase the orthostatic hypotensive activities of Mannitol.]
[J05AF06, abacavir, Mannitol may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE09, tipranavir, The serum concentration of Mannitol can be increased when it is combined with Tipranavir.]
[N07XX13, valbenazine, Mannitol may increase the excretion rate of Valbenazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BD03, safinamide, Safinamide may increase the orthostatic hypotensive activities of Mannitol.]
[J01MA23, delafloxacin, Mannitol may increase the excretion rate of Delafloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AF04, betrixaban, The serum concentration of Betrixaban can be increased when it is combined with Mannitol.]
[L01BC06, capecitabine, Mannitol may increase the excretion rate of Capecitabine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX59, enasidenib, The serum concentration of Mannitol can be increased when it is combined with Enasidenib.]
[L01EH02, neratinib, The serum concentration of Mannitol can be increased when it is combined with Neratinib.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Mannitol.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Mannitol.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Mannitol.]
[C07AB07, bisoprolol, Mannitol may increase the excretion rate of Bisoprolol which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DC10, cefprozil, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefprozil.]
[C07AA17, bopindolol, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Bopindolol.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Mannitol is combined with Nesiritide.]
[C03DA03, canrenone, The risk or severity of adverse effects can be increased when Canrenone is combined with Mannitol.]
[R03BA02, budesonide, Mannitol may increase the excretion rate of Budesonide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AB07, bumadizone, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Bumadizone.]
[A10BK04, ertugliflozin, The risk or severity of adverse effects can be increased when Ertugliflozin is combined with Mannitol.]
[R06AX18, acrivastine, Mannitol may increase the excretion rate of Acrivastine which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA01, captopril, The risk or severity of adverse effects can be increased when Mannitol is combined with Captopril.]
[L02BB05, apalutamide, The serum concentration of Mannitol can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, Mannitol may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[A06AC08, calcium polycarbophil, The risk or severity of adverse effects can be increased when Mannitol is combined with Calcium polycarbophil.]
[C07AG02, carvedilol, The serum concentration of Mannitol can be increased when it is combined with Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of hypotension can be increased when Fostamatinib is combined with Mannitol.]
[B02BX08, avatrombopag, The serum concentration of Avatrombopag can be increased when it is combined with Mannitol.]
[L04AA37, baricitinib, Mannitol may increase the excretion rate of Baricitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DE01, cefepime, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefepime.]
[J01DD10, cefetamet, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefetamet.]
[J01DD09, cefodizime, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefodizime.]
[J01DC11, ceforanide, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Ceforanide.]
[J01DD13, cefpodoxime, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefpodoxime.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Mannitol.]
[J01DD14, ceftibuten, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Ceftibuten.]
[J01GB14, plazomicin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Plazomicin.]
[C07AB08, celiprolol, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Celiprolol.]
[H01CC03, elagolix, The serum concentration of Mannitol can be increased when it is combined with Elagolix.]
[A16AX14, migalastat, Mannitol may increase the excretion rate of Migalastat which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX17, stiripentol, The excretion of Mannitol can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Lusutrombopag can be increased when it is combined with Mannitol.]
[L01EM04, duvelisib, The serum concentration of Duvelisib can be increased when it is combined with Mannitol.]
[L01EB07, dacomitinib, The serum concentration of Mannitol can be increased when it is combined with Dacomitinib.]
[J01AA14, sarecycline, The serum concentration of Mannitol can be increased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Omadacycline can be increased when it is combined with Mannitol.]
[S01GX12, cetirizine, Mannitol may increase the excretion rate of Cetirizine which could result in a lower serum level and potentially a reduction in efficacy.]
[D08AE05, chloroxylenol, Mannitol may increase the excretion rate of Chloroxylenol which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC05, lornoxicam, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Lornoxicam.]
[N07XX15, inotersen, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Inotersen.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Mannitol.]
[R03BB08, revefenacin, The serum concentration of Revefenacin can be increased when it is combined with Mannitol.]
[L01AD01, carmustine, Mannitol may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX12, larotrectinib, The serum concentration of Larotrectinib can be increased when it is combined with Mannitol.]
[L01EX13, gilteritinib, The serum concentration of Gilteritinib can be increased when it is combined with Mannitol.]
[L01XJ03, glasdegib, The serum concentration of Mannitol can be increased when it is combined with Glasdegib.]
[A06AX05, prucalopride, The risk or severity of adverse effects can be increased when Mannitol is combined with Prucalopride.]
[C09AA08, cilazapril, The risk or severity of adverse effects can be increased when Mannitol is combined with Cilazapril.]
[B01AC23, cilostazol, Mannitol may increase the excretion rate of Cilostazol which could result in a lower serum level and potentially a reduction in efficacy.]
[J01FA09, clarithromycin, The serum concentration of Mannitol can be increased when it is combined with Clarithromycin.]
[N06BA14, solriamfetol, Mannitol may increase the excretion rate of Solriamfetol which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EN01, erdafitinib, The serum concentration of Mannitol can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, Mannitol may increase the excretion rate of Clobazam which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AB05, castor oil, The risk or severity of adverse effects can be increased when Mannitol is combined with Castor oil.]
[C09CA06, candesartan, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Candesartan.]
[J01DC04, cefaclor, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefaclor.]
[J01DB05, cefadroxil, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefadroxil.]
[J01DC03, cefamandole, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefamandole.]
[J01DB07, cefatrizine, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefatrizine.]
[J01DB04, cefazolin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefazolin.]
[L02BB06, darolutamide, The serum concentration of Darolutamide can be increased when it is combined with Mannitol.]
[J01DC09, cefmetazole, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefmetazole.]
[J01DC06, cefonicid, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefonicid.]
[J01DD12, cefoperazone, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefoperazone.]
[J01DD01, cefotaxime, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefotaxime.]
[J01DC05, cefotetan, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefotetan.]
[J01DC07, cefotiam, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefotiam.]
[J01DC01, cefoxitin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefoxitin.]
[J01DD03, cefsulodin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefsulodin.]
[J01DD02, ceftazidime, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Ceftazidime.]
[C03BX03, cicletanine, The risk or severity of adverse effects can be increased when Cicletanine is combined with Mannitol.]
[J01DD07, ceftizoxime, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Ceftizoxime.]
[J01DD04, ceftriaxone, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Ceftriaxone.]
[S01AA27, cefuroxime, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefuroxime.]
[L01EJ02, fedratinib, The serum concentration of Mannitol can be increased when it is combined with Fedratinib.]
[L01EX14, entrectinib, The serum concentration of Mannitol can be increased when it is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Mannitol can be increased when it is combined with Pitolisant.]
[J01XX12, lefamulin, The serum concentration of Lefamulin can be increased when it is combined with Mannitol.]
[N04CX01, istradefylline, The serum concentration of Mannitol can be increased when it is combined with Istradefylline.]
[C03AA09, cyclothiazide, The risk or severity of adverse effects can be increased when Cyclothiazide is combined with Mannitol.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Mannitol.]
[A06AB03, danthron, The risk or severity of adverse effects can be increased when Mannitol is combined with Dantron.]
[J01XX09, daptomycin, Mannitol may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB01, cephalexin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cephalexin.]
[J01DB02, cephaloridine, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefaloridine.]
[J01DB03, cephalothin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefalotin.]
[J01DB08, cephapirin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefapirin.]
[J01DB09, cephradine, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefradine.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Trastuzumab emtansine can be increased when it is combined with Mannitol.]
[N02CC08, lasmiditan, The serum concentration of Mannitol can be increased when it is combined with Lasmiditan.]
[A16AX16, givosiran, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Givosiran.]
[M09AX08, golodirsen, Mannitol may increase the excretion rate of Golodirsen which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Mannitol.]
[L01FX13, enfortumab vedotin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Mannitol.]
[S01XA12, dexpanthenol, Mannitol may increase the excretion rate of Dexpanthenol which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX03, dezocine, The therapeutic efficacy of Mannitol can be decreased when used in combination with Dezocine.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be increased when it is combined with Mannitol.]
[L01XX72, tazemetostat, The serum concentration of Tazemetostat can be increased when it is combined with Mannitol.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Mannitol.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be increased when it is combined with Mannitol.]
[R02AA03, dichlorobenzyl alcohol, Mannitol may increase the excretion rate of Dichlorobenzyl alcohol which could result in a lower serum level and potentially a reduction in efficacy.]
[G03DB08, dienogest, Mannitol may increase the excretion rate of Dienogest which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AA08, dihydrocodeine, The therapeutic efficacy of Mannitol can be decreased when used in combination with Dihydrocodeine.]
[M01AH02, rofecoxib, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Rofecoxib.]
[C08CA16, clevidipine, Mannitol may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BD07, dronedarone, The serum concentration of Mannitol can be increased when it is combined with Dronedarone.]
[C02AA06, methoserpidine, Mannitol may increase the hypotensive activities of Methoserpidine.]
[L01EH03, tucatinib, Tucatinib may decrease the excretion rate of Mannitol which could result in a higher serum level.]
[L01EX17, capmatinib, The serum concentration of Mannitol can be increased when it is combined with Capmatinib.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Mannitol is combined with Opicapone.]
[M01AC04, droxicam, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Droxicam.]
[L01EX19, ripretinib, The serum concentration of Mannitol can be increased when it is combined with Ripretinib.]
[V08CA05, mangafodipir, Mannitol may increase the excretion rate of Mangafodipir which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA27, dexketoprofen, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Dexketoprofen.]
[C08CA17, levamlodipine, The therapeutic efficacy of Mannitol can be decreased when used in combination with Levamlodipine.]
[J05AX29, fostemsavir, The serum concentration of Fostemsavir can be increased when it is combined with Mannitol.]
[L01FX15, belantamab mafodotin, The serum concentration of Belantamab mafodotin can be increased when it is combined with Mannitol.]
[N02AX07, oliceridine, The therapeutic efficacy of Mannitol can be decreased when used in combination with Oliceridine.]
[P01BA01, chloroquine, Mannitol may increase the excretion rate of Chloroquine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX23, pralsetinib, The serum concentration of Mannitol can be increased when it is combined with Pralsetinib.]
[C03AA04, chlorothiazide, The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Mannitol.]
[N05AA01, chlorpromazine, Mannitol may increase the excretion rate of Chlorpromazine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BB02, chlorpropamide, Mannitol may increase the excretion rate of Chlorpropamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA04, chlorthalidone, The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Mannitol.]
[M03BB03, chlorzoxazone, Mannitol may increase the excretion rate of Chlorzoxazone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA07, ethenzamide, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Ethenzamide.]
[N02BA03, choline salicylate, Mannitol may increase the excretion rate of Choline salicylate which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BX18, vinpocetine, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Vinpocetine.]
[M01AB08, etodolac, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Etofenamate.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be increased when it is combined with Mannitol.]
[A16AX20, lonafarnib, The serum concentration of Mannitol can be increased when it is combined with Lonafarnib.]
[L02BX04, relugolix, The serum concentration of Relugolix can be increased when it is combined with Mannitol.]
[M01AX25, chondroitin sulfates, Mannitol may increase the excretion rate of Chondroitin sulfate which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AD03, voclosporin, The serum concentration of Mannitol can be increased when it is combined with Voclosporin.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Mannitol is combined with Vericiguat.]
[L01EX21, tepotinib, The serum concentration of Mannitol can be increased when it is combined with Tepotinib.]
[L01EX25, umbralisib, The serum concentration of Mannitol can be increased when it is combined with Umbralisib.]
[V03AF12, trilaciclib, The serum concentration of Trilaciclib can be increased when it is combined with Mannitol.]
[M01AE05, fenbufen, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Fenbufen.]
[C01CA19, fenoldopam, Mannitol may increase the excretion rate of Fenoldopam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD15, cefdinir, Mannitol may increase the excretion rate of Cefdinir which could result in a lower serum level and potentially a reduction in efficacy.]
[S02BA08, fluocinolone acetonide, Mannitol may increase the excretion rate of Fluocinolone acetonide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG07, flupirtine, Mannitol may increase the excretion rate of Flupirtine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Mannitol.]
[L01EK03, tivozanib, The serum concentration of Tivozanib can be increased when it is combined with Mannitol.]
[H04AA02, dasiglucagon, Mannitol may increase the hypotensive activities of Dasiglucagon.]
[L01FX22, loncastuximab tesirine, The serum concentration of Loncastuximab tesirine can be increased when it is combined with Mannitol.]
[A02BA01, cimetidine, Mannitol may increase the excretion rate of Cimetidine which could result in a lower serum level and potentially a reduction in efficacy.]
[V08CA04, gadoteridol, Mannitol may increase the excretion rate of Gadoteridol which could result in a lower serum level and potentially a reduction in efficacy.]
[N07CA02, cinnarizine, The risk or severity of hyperkalemia can be increased when Cinnarizine is combined with Mannitol.]
[L01XX73, sotorasib, The serum concentration of Mannitol can be increased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, Mannitol may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XA01, cisplatin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cisplatin.]
[C03DA05, finerenone, The risk or severity of adverse effects can be increased when Finerenone is combined with Mannitol.]
[L04AA48, belumosudil, The serum concentration of Mannitol can be increased when it is combined with Belumosudil.]
[V09AB03, ioflupane I-123, Mannitol may increase the excretion rate of Ioflupane I-123 which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AA01, technetium Tc 99m exametazime, Mannitol may increase the excretion rate of Technetium Tc-99m exametazime which could result in a lower serum level and potentially a reduction in efficacy.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Mannitol.]
[V09AX06, florbetaben f-18, Mannitol may increase the excretion rate of Florbetaben (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA06, asciminib, The serum concentration of Mannitol can be increased when it is combined with Asciminib.]
[J05AX10, maribavir, The serum concentration of Mannitol can be increased when it is combined with Maribavir.]
[D11AH08, abrocitinib, The serum concentration of Mannitol can be increased when it is combined with Abrocitinib.]
[J04BA01, clofazimine, The serum concentration of Mannitol can be increased when it is combined with Clofazimine.]
[B06AX04, mitapivat, The serum concentration of Mannitol can be increased when it is combined with Mitapivat.]
[N01BB10, levobupivacaine, Mannitol may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EJ03, pacritinib, The serum concentration of Mannitol can be increased when it is combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Clomifene can be increased when it is combined with Mannitol.]
[N06AA04, clomipramine, Mannitol may increase the excretion rate of Clomipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AE01, clonazepam, Mannitol may increase the excretion rate of Clonazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EA04, clonidine, The risk or severity of adverse effects can be increased when Clonidine is combined with Mannitol.]
[J05AH02, oseltamivir, Mannitol may increase the excretion rate of Oseltamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA03, clopamide, The risk or severity of adverse effects can be increased when Clopamide is combined with Mannitol.]
[N05AH02, clozapine, Mannitol may increase the excretion rate of Clozapine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EN04, futibatinib, The serum concentration of Futibatinib can be increased when it is combined with Mannitol.]
[A10BK06, sotagliflozin, The serum concentration of Mannitol can be increased when it is combined with Sotagliflozin.]
[J01GB12, arbekacin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Arbekacin.]
[C02KB01, metyrosine, Mannitol may increase the hypotensive activities of Metyrosine.]
[M01AX13, proquazone, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Proquazone.]
[R05DA04, codeine, The therapeutic efficacy of Mannitol can be decreased when used in combination with Codeine.]
[M04AC01, colchicine, Mannitol may increase the excretion rate of Colchicine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XB01, colistin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Colistin.]
[J01DE02, cefpirome, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefpirome.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Mannitol is combined with Desflurane.]
[A04AA03, tropisetron, Mannitol may increase the excretion rate of Tropisetron which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BX03, nateglinide, Mannitol may increase the excretion rate of Nateglinide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Imidazole salicylate.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Mannitol.]
[B01AC10, indobufen, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Indobufen.]
[J05AB14, valganciclovir, Mannitol may increase the excretion rate of Valganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C05BB03, invert sugar, Mannitol may increase the excretion rate of Invert sugar which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB09, iodixanol, Mannitol may increase the excretion rate of Iodixanol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB05, iopromide, Mannitol may increase the excretion rate of Iopromide which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB07, ioversol, Mannitol may increase the excretion rate of Ioversol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB12, ioxilan, Mannitol may increase the excretion rate of Ioxilan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH03, valdecoxib, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Valdecoxib.]
[N02CC05, almotriptan, Mannitol may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH04, parecoxib, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Parecoxib.]
[J02AC02, itraconazole, The serum concentration of Mannitol can be increased when it is combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Bemiparin.]
[S01AD03, acyclovir, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Acyclovir.]
[N05BA10, ketazolam, Mannitol may increase the excretion rate of Ketazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AA06, kebuzone, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Kebuzone.]
[J02AC04, posaconazole, The serum concentration of Posaconazole can be increased when it is combined with Mannitol.]
[C08CA09, lacidipine, Mannitol may increase the hypotensive activities of Lacidipine.]
[A06AD12, lactitol, The risk or severity of adverse effects can be increased when Mannitol is combined with Lactitol.]
[N03AX09, lamotrigine, Mannitol may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07BC04, lofexidine, Mannitol may increase the excretion rate of Lofexidine which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AB09, lonazolac, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Loxoprofen.]
[J01DC08, loracarbef, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Loracarbef.]
[C09AA03, lisinopril, Mannitol may increase the excretion rate of Lisinopril which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AD01, magnesium carbonate, The risk or severity of adverse effects can be increased when Mannitol is combined with Magnesium carbonate.]
[C08CA11, manidipine, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Manidipine.]
[C07AA14, mepindolol, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Mepindolol.]
[J01DH02, meropenem, Mannitol may increase the excretion rate of Meropenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AX01, cyclandelate, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Cyclandelate.]
[C03DA04, eplerenone, The risk or severity of adverse effects can be increased when Eplerenone is combined with Mannitol.]
[N05AD03, metylperon, Mannitol may increase the excretion rate of Melperone which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA07, cyclopenthiazide, The risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Mannitol.]
[J05AF07, tenofovir disoproxil, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Tenofovir disoproxil.]
[N06AX07, minaprine, Minaprine may increase the orthostatic hypotensive activities of Mannitol.]
[S01XA18, cyclosporine, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the orthostatic hypotensive activities of Mannitol.]
[C09AA13, moexipril, The risk or severity of adverse effects can be increased when Moexipril is combined with Mannitol.]
[M02AA02, mofebutazone, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Morniflumate.]
[C03XA02, conivaptan, The serum concentration of Mannitol can be increased when it is combined with Conivaptan.]
[C02AC05, moxonidine, The risk or severity of adverse effects can be increased when Mannitol is combined with Moxonidine.]
[G04BE09, vardenafil, The serum concentration of Mannitol can be increased when it is combined with Vardenafil.]
[M01AH05, etoricoxib, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Etoricoxib.]
[L01AX04, dacarbazine, Mannitol may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DA01, dactinomycin, The serum concentration of Dactinomycin can be increased when it is combined with Mannitol.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Dantrolene.]
[C02CC04, debrisoquin, Mannitol may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Nabilone is combined with Mannitol.]
[M01AX01, nabumetone, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Nabumetone.]
[N07BB05, nalmefene, Mannitol may increase the excretion rate of Nalmefene which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA15, potassium lactate, The risk or severity of adverse effects can be increased when Mannitol is combined with Potassium lactate.]
[C07AB12, nebivolol, The risk or severity of adverse effects can be increased when Mannitol is combined with Nebivolol.]
[S01GX04, nedocromil, Mannitol may increase the excretion rate of Nedocromil which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX06, nefazodone, Mannitol may increase the excretion rate of Nefazodone which could result in a lower serum level and potentially a reduction in efficacy.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Mannitol.]
[L02BB02, nilutamide, Mannitol may increase the excretion rate of Nilutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA23, theodrenaline, The risk or severity of Cardiac Arrhythmia can be increased when Theodrenaline is combined with Mannitol.]
[R05DA06, normethadone, The therapeutic efficacy of Mannitol can be decreased when used in combination with Normethadone.]
[B01AX05, fondaparinux, Mannitol may increase the excretion rate of Fondaparinux which could result in a lower serum level and potentially a reduction in efficacy.]
[A07EC03, olsalazine, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Olsalazine.]
[N06AA01, desipramine, Mannitol may increase the excretion rate of Desipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[H01BA02, desmopressin, Mannitol may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CH02, indigo carmine, Mannitol may increase the excretion rate of Indigotindisulfonic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DH03, ertapenem, Mannitol may increase the excretion rate of Ertapenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C09XA02, aliskiren, The risk or severity of adverse effects can be increased when Mannitol is combined with Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Oxaprozin.]
[N06BA02, dextroamphetamine, Mannitol may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AC01, dextromoramide, The therapeutic efficacy of Mannitol can be decreased when used in combination with Dextromoramide.]
[N07BC06, heroin, The therapeutic efficacy of Mannitol can be decreased when used in combination with Diamorphine.]
[P03AC04, permethrin, Mannitol may increase the excretion rate of Permethrin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA01, diazepam, Mannitol may increase the excretion rate of Diazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AH01, diazoxide, The risk or severity of adverse effects can be increased when Mannitol is combined with Diazoxide.]
[R05DA08, pholcodine, Mannitol may increase the excretion rate of Pholcodine which could result in a lower serum level and potentially a reduction in efficacy.]
[M05BA02, clodronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Mannitol is combined with Clodronic acid.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Diclofenamide is combined with Mannitol.]
[S01BC03, diclofenac, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Diclofenac.]
[J05AD01, foscarnet, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Foscarnet.]
[A03AA07, dicyclomine, Mannitol may increase the excretion rate of Dicyclomine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF02, didanosine, Mannitol may increase the excretion rate of Didanosine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DG01, pinacidil, Mannitol may increase the hypotensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Pinaverium.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Mannitol is combined with Pipamperone.]
[L01DC04, ixabepilone, The serum concentration of Mannitol can be increased when it is combined with Ixabepilone.]
[C03CA03, piretanide, The risk or severity of adverse effects can be increased when Piretanide is combined with Mannitol.]
[C08CA03, isradipine, Mannitol may increase the excretion rate of Isradipine which could result in a lower serum level and potentially a reduction in efficacy.]
[D07XC04, diflucortolone, Mannitol may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA11, diflunisal, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Diflunisal.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be increased when it is combined with Mannitol.]
[C01AA05, digoxin, Mannitol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02DB01, dihydralazine, Mannitol may increase the hypotensive activities of Dihydralazine.]
[N02AA03, hydromorphone, Mannitol may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX04, lenalidomide, Mannitol may increase the excretion rate of Lenalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE08, atazanavir, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Atazanavir.]
[B01AC21, treprostinil, Mannitol may increase the hypotensive activities of Treprostinil.]
[H03BC01, potassium perchlorate, Mannitol may increase the excretion rate of Potassium perchlorate which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB04, pralidoxime, Mannitol may increase the excretion rate of Pralidoxime which could result in a lower serum level and potentially a reduction in efficacy.]
[C08DB01, diltiazem, The risk or severity of adverse effects can be increased when Diltiazem is combined with Mannitol.]
[V03AB09, dimercaprol, Mannitol may increase the excretion rate of Dimercaprol which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AX03, dimethyl sulfoxide, Mannitol may increase the excretion rate of Dimethyl sulfoxide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BB04, propyphenazone, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Proglumetacin.]
[C05CA03, diosmin, The serum concentration of Mannitol can be increased when it is combined with Diosmin.]
[A07DA01, diphenoxylate, The therapeutic efficacy of Mannitol can be decreased when used in combination with Diphenoxylate.]
[C09AA06, quinapril, The risk or severity of adverse effects can be increased when Mannitol is combined with Quinapril.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Mannitol is combined with Dipyridamole.]
[C09AA05, ramipril, The risk or severity of adverse effects can be increased when Ramipril is combined with Mannitol.]
[S01XA23, sirolimus, The serum concentration of Sirolimus can be increased when it is combined with Mannitol.]
[S01AX06, resorcinol, Mannitol may increase the excretion rate of Resorcinol which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BA03, disopyramide, Mannitol may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.]
[S02AA12, rifamycin SV, The serum concentration of Mannitol can be increased when it is combined with Rifamycin.]
[N05AX08, risperidone, Mannitol may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, Mannitol may increase the excretion rate of Levocetirizine which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB09, ropivacaine, Mannitol may increase the excretion rate of Ropivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[C03XA01, tolvaptan, The risk or severity of adverse effects can be increased when Tolvaptan is combined with Mannitol.]
[L01XG01, bortezomib, The serum concentration of Bortezomib can be increased when it is combined with Mannitol.]
[G04BE08, tadalafil, Mannitol may increase the excretion rate of Tadalafil which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC05, ketorolac, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Ketorolac.]
[C02KX02, ambrisentan, The serum concentration of Ambrisentan can be increased when it is combined with Mannitol.]
[C01EB18, ranolazine, The serum concentration of Mannitol can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Salsalate.]
[H05BA01, salmon calcitonin, Mannitol may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA07, dobutamine, Mannitol may increase the excretion rate of Dobutamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA04, dopamine, Mannitol may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA12, doxepin, Mannitol may increase the excretion rate of Doxepin which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AB06, sennosides, USP, The risk or severity of adverse effects can be increased when Mannitol is combined with Sennosides.]
[J01AA02, doxycycline, Mannitol may increase the excretion rate of Doxycycline which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Mannitol is combined with Sevoflurane.]
[A08AA10, sibutramine, Mannitol may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA01, simvastatin, The serum concentration of Mannitol can be increased when it is combined with Simvastatin.]
[V03AG05, sodium phosphate, Mannitol may increase the nephrotoxic activities of Sodium phosphate, monobasic.]
[A12CA02, sodium sulfate, The risk or severity of adverse effects can be increased when Mannitol is combined with Sodium sulfate.]
[C09AA11, spirapril, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Spirapril.]
[R03DA01, dyphylline, Mannitol may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CC01, sumatriptan, Mannitol may increase the excretion rate of Sumatriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX07, edrophonium, Mannitol may increase the excretion rate of Edrophonium which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB13, talinolol, The serum concentration of Talinolol can be increased when it is combined with Mannitol.]
[L01AX03, temozolomide, Mannitol may increase the excretion rate of Temozolomide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC02, tenoxicam, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Tenoxicam.]
[G04CA03, terazosin, The risk or severity of adverse effects can be increased when Mannitol is combined with Terazosin.]
[G04BD05, terodiline, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Terodiline.]
[C07AA16, tertatolol, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Tertatolol.]
[C09AA02, enalapril, The risk or severity of adverse effects can be increased when Enalapril is combined with Mannitol.]
[M01AG02, tolfenamic acid, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the orthostatic hypotensive activities of Mannitol.]
[N06BA09, atomoxetine, Mannitol may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX11, topiramate, Mannitol may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BA02, toremifene, The serum concentration of Mannitol can be increased when it is combined with Toremifene.]
[C03CA04, torsemide, The risk or severity of adverse effects can be increased when Torasemide is combined with Mannitol.]
[C09AA10, trandolapril, The risk or severity of adverse effects can be increased when Trandolapril is combined with Mannitol.]
[N05CC01, chloral hydrate, Mannitol may increase the excretion rate of Chloral hydrate which could result in a lower serum level and potentially a reduction in efficacy.]
[C02CA06, urapidil, Mannitol may increase the hypotensive activities of Urapidil.]
[S01FB02, ephedrine, The risk or severity of Cardiac Arrhythmia can be increased when Ephedrine is combined with Mannitol.]
[N06AX16, venlafaxine, Mannitol may increase the excretion rate of Venlafaxine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01GA03, xylometazoline, The therapeutic efficacy of Mannitol can be decreased when used in combination with Xylometazoline.]
[C08CA12, mepirodipine, The risk or severity of adverse effects can be increased when Mannitol is combined with Barnidipine.]
[S01EA01, epinephrine, The risk or severity of Cardiac Arrhythmia can be increased when Epinephrine is combined with Mannitol.]
[C09AA15, zofenopril, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Zofenopril.]
[M01AB04, zomepirac, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Zomepirac.]
[N03AX15, zonisamide, The serum concentration of Mannitol can be increased when it is combined with Zonisamide.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Mannitol.]
[L01XA02, carboplatin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Carboplatin.]
[C02AC02, guanfacine, Mannitol may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC11, iloprost, The risk or severity of adverse effects can be increased when Mannitol is combined with Iloprost.]
[L03AX05, pidotimod, Mannitol may increase the excretion rate of Pidotimod which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA17, erythromycin, The serum concentration of Mannitol can be increased when it is combined with Erythromycin.]
[N05CD04, estazolam, Mannitol may increase the excretion rate of Estazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC02, pantoprazole, Mannitol may increase the excretion rate of Pantoprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[G03CA03, estradiol, Mannitol may increase the excretion rate of Estradiol which could result in a lower serum level and potentially a reduction in efficacy.]
[G03CA57, estrogens, conjugated (USP), Mannitol may increase the excretion rate of Conjugated estrogens which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK02, ethambutol, Mannitol may increase the excretion rate of Ethambutol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08CA03, gadodiamide, Mannitol may increase the excretion rate of Gadodiamide which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Mannitol is combined with Amifostine.]
[C01BD05, ibutilide, Mannitol may increase the excretion rate of Ibutilide which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AD01, ethosuximide, The risk or severity of hyperkalemia can be increased when Ethosuximide is combined with Mannitol.]
[M01AC06, meloxicam, The therapeutic efficacy of Mannitol can be decreased when used in combination with Meloxicam.]
[S01XA06, ethylmorphine, The therapeutic efficacy of Mannitol can be decreased when used in combination with Ethylmorphine.]
[N01AX07, etomidate, Mannitol may increase the excretion rate of Etomidate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Mannitol.]
[L04AD02, tacrolimus, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Tacrolimus.]
[P01AX07, trimetrexate, Mannitol may increase the excretion rate of Trimetrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX12, bupropion, Mannitol may increase the excretion rate of Bupropion which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB08, fluvoxamine, Mannitol may increase the excretion rate of Fluvoxamine which could result in a lower serum level and potentially a reduction in efficacy.]
[L02AE02, leuprolide, Mannitol may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA03, pravastatin, The serum concentration of Mannitol can be increased when it is combined with Pravastatin.]
[M01CB01, gold sodium thiomalate, Mannitol may increase the excretion rate of Sodium aurothiomalate which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA05, dextran, Mannitol may increase the excretion rate of Dextran which could result in a lower serum level and potentially a reduction in efficacy.]
[M05BA01, etidronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Mannitol is combined with Etidronic acid.]
[V03AF02, dexrazoxane, Mannitol may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AA01, levocarnitine, Mannitol may increase the excretion rate of Levocarnitine which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA02, felodipine, The risk or severity of adverse effects can be increased when Mannitol is combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Fendiline.]
[M01AE04, fenoprofen, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Fenoprofen.]
[N02AB03, fentanyl, Mannitol may increase the excretion rate of Fentanyl which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC02, albuterol, Mannitol may increase the excretion rate of Salbutamol which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BB06, clofarabine, Mannitol may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07AX03, cevimeline, Mannitol may increase the excretion rate of Cevimeline which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD02, flavoxate, Mannitol may increase the excretion rate of Flavoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG04, floctafenine, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Floctafenine.]
[J02AC01, fluconazole, The serum concentration of Mannitol can be increased when it is combined with Fluconazole.]
[J02AX01, flucytosine, Mannitol may increase the excretion rate of Flucytosine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB25, flumazenil, Mannitol may increase the excretion rate of Flumazenil which could result in a lower serum level and potentially a reduction in efficacy.]
[N07CA03, flunarizine, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Flunarizine.]
[V03AZ01, ethanol, Ethanol may increase the hypotensive activities of Mannitol.]
[L01BC09, floxuridine, Mannitol may increase the excretion rate of Floxuridine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD01, flurazepam, Mannitol may increase the excretion rate of Flurazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC04, flurbiprofen, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Fluspirilene.]
[L02BB01, flutamide, Mannitol may increase the excretion rate of Flutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX02, folic acid, Mannitol may increase the excretion rate of Folic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[S02AA17, fosfomycin, Mannitol may increase the excretion rate of Fosfomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA07, framycetin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Framycetin.]
[L01BC03, tegafur, Mannitol may increase the excretion rate of Tegafur which could result in a lower serum level and potentially a reduction in efficacy.]
[G01AX06, furazolidone, Furazolidone may increase the orthostatic hypotensive activities of Mannitol.]
[J05AE10, darunavir, The serum concentration of Darunavir can be increased when it is combined with Mannitol.]
[C03CA01, furosemide, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Furosemide.]
[M05BA04, alendronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Mannitol is combined with Alendronic acid.]
[N05CF04, eszopiclone, Mannitol may increase the excretion rate of Eszopiclone which could result in a lower serum level and potentially a reduction in efficacy.]
[C08DA02, gallopamil, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Gallopamil.]
[S01AD09, ganciclovir, Mannitol may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Mannitol.]
[C10AB04, gemfibrozil, Mannitol may increase the excretion rate of Gemfibrozil which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XA03, telavancin, Mannitol may increase the excretion rate of Telavancin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA02, dasatinib, The serum concentration of Dasatinib can be increased when it is combined with Mannitol.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Mannitol.]
[N03AD03, methsuximide, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Methsuximide.]
[N01AH02, alfentanil, The therapeutic efficacy of Mannitol can be decreased when used in combination with Alfentanil.]
[L01EH01, lapatinib, The serum concentration of Mannitol can be increased when it is combined with Lapatinib.]
[A10BB07, glipizide, Mannitol may increase the excretion rate of Glipizide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CM18, dexmedetomidine, Mannitol may increase the excretion rate of Dexmedetomidine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX01, glycerin, The risk or severity of adverse effects can be increased when Mannitol is combined with Glycerin.]
[C05AE01, nitroglycerin, The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Mannitol.]
[C02CA04, doxazosin, The risk or severity of adverse effects can be increased when Doxazosin is combined with Mannitol.]
[L01EX02, sorafenib, The serum concentration of Mannitol can be increased when it is combined with Sorafenib.]
[C07AB09, esmolol, The risk or severity of adverse effects can be increased when Esmolol is combined with Mannitol.]
[M01CB04, aurothioglucose, Mannitol may increase the excretion rate of Aurothioglucose which could result in a lower serum level and potentially a reduction in efficacy.]
[S01LA03, pegaptanib, Mannitol may increase the excretion rate of Pegaptanib which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA09, fosinopril, Mannitol may increase the excretion rate of Fosinopril which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EX01, guanethidine, Mannitol may increase the excretion rate of Guanethidine which could result in a lower serum level and potentially a reduction in efficacy.]
[L02AE03, goserelin, Mannitol may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD01, haloperidol, Mannitol may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Mannitol is combined with Halothane.]
[N05AH04, quetiapine, Mannitol may increase the excretion rate of Quetiapine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BX13, idebenone, Mannitol may increase the excretion rate of Idebenone which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Mannitol.]
[M04AA01, allopurinol, Mannitol may increase the excretion rate of Allopurinol which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA01, losartan, The risk or severity of adverse effects can be increased when Losartan is combined with Mannitol.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Heparin.]
[B05CB03, magnesium citrate, The risk or severity of adverse effects can be increased when Mannitol is combined with Magnesium citrate.]
[G03DC01, allylestrenol, Mannitol may increase the excretion rate of Allylestrenol which could result in a lower serum level and potentially a reduction in efficacy.]
[A07EC02, mesalamine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Mannitol.]
[C01CE02, milrinone, Mannitol may increase the excretion rate of Milrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[A12CD02, sodium monofluorophosphate, The risk or severity of adverse effects can be increased when Mannitol is combined with Sodium fluorophosphate.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Mannitol.]
[C08CA10, nilvadipine, The risk or severity of adverse effects can be increased when Mannitol is combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Nimesulide.]
[C09AA04, perindopril, Mannitol may increase the excretion rate of Perindopril which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DB02, hydralazine, Mannitol may increase the excretion rate of Hydralazine which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA03, hydrochlorothiazide, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Hydrochlorothiazide.]
[R05DA03, hydrocodone, The therapeutic efficacy of Mannitol can be decreased when used in combination with Hydrocodone.]
[C03AA02, hydroflumethiazide, The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Mannitol.]
[B05XA17, potassium acetate, Mannitol may increase the excretion rate of Potassium acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Mannitol.]
[A12BA02, potassium citrate, The risk or severity of adverse effects can be increased when Potassium citrate is combined with Mannitol.]
[V03AB33, hydroxocobalamin, Mannitol may increase the excretion rate of Hydroxocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD06, propiverine, Mannitol may increase the excretion rate of Propiverine which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA07, hetastarch, Mannitol may increase the excretion rate of Hydroxyethyl Starch which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AC06, rilmenidine, Mannitol may increase the hypotensive activities of Rilmenidine.]
[M05BA07, risedronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Mannitol is combined with Risedronic acid.]
[R02AX02, ibuprofen, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Ibuprofen.]
[B05XA08, sodium acetate, Mannitol may increase the excretion rate of Sodium acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AD21, sodium tartrate, The risk or severity of adverse effects can be increased when Mannitol is combined with Sodium tartrate.]
[L01AA06, ifosfamide, Mannitol may increase the excretion rate of Ifosfamide which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AH03, sufentanil, The therapeutic efficacy of Mannitol can be decreased when used in combination with Sufentanil.]
[N06AA02, imipramine, Mannitol may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Mannitol is combined with Paclitaxel.]
[R01AD07, tixocortol, Mannitol may increase the excretion rate of Tixocortol which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Mannitol.]
[L01CE01, topotecan, Mannitol may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA11, indapamide, The risk or severity of adverse effects can be increased when Indapamide is combined with Mannitol.]
[S01BC01, indomethacin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Indomethacin.]
[C02CA02, indoramin, The risk or severity of adverse effects can be increased when Mannitol is combined with Indoramin.]
[A11HA07, inositol, Mannitol may increase the excretion rate of Inositol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX17, milnacipran, Mannitol may increase the excretion rate of Milnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[S01XA28, varenicline, Mannitol may increase the excretion rate of Varenicline which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH01, sitagliptin, Mannitol may increase the excretion rate of Sitagliptin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA12, alprazolam, Mannitol may increase the excretion rate of Alprazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH02, ramelteon, Mannitol may increase the excretion rate of Ramelteon which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA01, alprenolol, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Alprenolol.]
[C03BA02, quinethazone, The risk or severity of adverse effects can be increased when Quinethazone is combined with Mannitol.]
[V03AB01, ipecac, Mannitol may increase the excretion rate of Ipecac which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF05, iproniazid, Iproniazid may increase the orthostatic hypotensive activities of Mannitol.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the orthostatic hypotensive activities of Mannitol.]
[C09AA16, imidapril, The risk or severity of adverse effects can be increased when Mannitol is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Mannitol is combined with Isoflurane.]
[J04AC01, isoniazid, Mannitol may increase the excretion rate of Isoniazid which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AX05, inosine pranobex, Mannitol may increase the excretion rate of Inosine pranobex which could result in a lower serum level and potentially a reduction in efficacy.]
[C01DA14, isosorbide mononitrate, Mannitol may increase the excretion rate of Isosorbide mononitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Mannitol is combined with Isosorbide dinitrate.]
[D10BA01, isotretinoin, Mannitol may increase the excretion rate of Isotretinoin which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AA01, isoxsuprine, The risk or severity of adverse effects can be increased when Mannitol is combined with Isoxsuprine.]
[S01AA24, kanamycin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Kanamycin.]
[N01AX03, ketamine, Mannitol may increase the excretion rate of Ketamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02KD01, ketanserin, Mannitol may increase the hypotensive activities of Ketanserin.]
[B01AC22, prasugrel, Mannitol may increase the excretion rate of Prasugrel which could result in a lower serum level and potentially a reduction in efficacy.]
[J02AB02, ketoconazole, The serum concentration of Mannitol can be increased when it is combined with Ketoconazole.]
[H02CA04, levoketoconazole, The serum concentration of Mannitol can be increased when it is combined with Levoketoconazole.]
[N05AH03, olanzapine, The risk or severity of adverse effects can be increased when Olanzapine is combined with Mannitol.]
[M02AA10, ketoprofen, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Ketoprofen.]
[N04BC09, rotigotine, The risk or severity of adverse effects can be increased when Mannitol is combined with Rotigotine.]
[D10AX03, azelaic acid, Mannitol may increase the excretion rate of Azelaic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AE11, tiaprofenic acid, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Tiaprofenic acid.]
[C07AG01, labetalol, Mannitol may increase the excretion rate of Labetalol which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BB01, amantadine, Mannitol may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA05, deserpidine, Mannitol may increase the hypotensive activities of Deserpidine.]
[A06AD11, lactulose, The risk or severity of adverse effects can be increased when Mannitol is combined with Lactulose.]
[A06AX03, lubiprostone, The risk or severity of adverse effects can be increased when Mannitol is combined with Lubiprostone.]
[C03CC01, ethacrynic acid, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Etacrynic acid.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Mannitol is combined with Levodopa.]
[C08EX01, lidoflazine, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Lidoflazine.]
[S01AA21, amikacin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Amikacin.]
[C03DB01, amiloride, The risk or severity of adverse effects can be increased when Amiloride is combined with Mannitol.]
[A07DA03, loperamide, The serum concentration of Loperamide can be increased when it is combined with Mannitol.]
[N05BA06, lorazepam, Mannitol may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AH01, loxapine, The serum concentration of Mannitol can be increased when it is combined with Loxapine.]
[L01EG01, temsirolimus, The serum concentration of Mannitol can be increased when it is combined with Temsirolimus.]
[G04BX01, magnesium hydroxide, The risk or severity of adverse effects can be increased when Mannitol is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The risk or severity of adverse effects can be increased when Mannitol is combined with Magnesium oxide.]
[V04CC02, magnesium sulfate, The risk or severity of adverse effects can be increased when Mannitol is combined with Magnesium sulfate.]
[L01BA05, pralatrexate, Mannitol may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA03, nilotinib, The serum concentration of Mannitol can be increased when it is combined with Nilotinib.]
[M01AG01, mefenamic acid, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Mefenamic acid.]
[C01DA05, pentaerythritol tetranitrate, Mannitol may increase the excretion rate of Pentaerythritol tetranitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Mannitol may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.]
[C02BB01, mecamylamine, Mannitol may increase the excretion rate of Mecamylamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA18, meclofenamic acid, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Meclofenamic acid.]
[A06AB07, cascara sagrada, The risk or severity of adverse effects can be increased when Mannitol is combined with Frangula purshiana bark.]
[P01BC02, mefloquine, The serum concentration of Mannitol can be increased when it is combined with Mefloquine.]
[C03BA05, mefruside, The risk or severity of adverse effects can be increased when Mefruside is combined with Mannitol.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Dalteparin.]
[N06DX01, memantine, Mannitol may increase the excretion rate of Memantine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AB02, meperidine, Mannitol may increase the excretion rate of Meperidine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Mannitol.]
[N01BB03, mepivacaine, Mannitol may increase the excretion rate of Mepivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX05, meptazinol, The therapeutic efficacy of Mannitol can be decreased when used in combination with Meptazinol.]
[G04BX16, tiopronin, Mannitol may increase the excretion rate of Tiopronin which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BC01, mersalyl, The risk or severity of adverse effects can be increased when Mersalyl is combined with Mannitol.]
[N05AX13, paliperidone, The serum concentration of Mannitol can be increased when it is combined with Paliperidone.]
[A10BA02, metformin, Mannitol may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.]
[N07BC02, methadone, Mannitol may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BA03, methamphetamine, Mannitol may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF05, lamivudine, Mannitol may increase the excretion rate of Lamivudine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Methazolamide is combined with Mannitol.]
[H03BB02, methimazole, Mannitol may increase the excretion rate of Methimazole which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BA04, pemetrexed, Mannitol may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Mannitol.]
[A11HA02, pyridoxine, Mannitol may increase the excretion rate of Pyridoxine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Mannitol is combined with Ziconotide.]
[L04AX03, methotrexate, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Methotrexate.]
[D05BA02, methoxsalen, Mannitol may increase the excretion rate of Methoxsalen which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA08, methyclothiazide, The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Mannitol.]
[A06AC06, methylcellulose, The risk or severity of adverse effects can be increased when Mannitol is combined with Methylcellulose.]
[C02AB01, methyldopa, Mannitol may increase the excretion rate of Methyldopa which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CG05, methylene blue, Methylene blue may increase the orthostatic hypotensive activities of Mannitol.]
[G03EK01, methyltestosterone, Mannitol may increase the excretion rate of Methyltestosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[A03FA01, metoclopramide, Mannitol may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA08, metolazone, The risk or severity of adverse effects can be increased when Metolazone is combined with Mannitol.]
[C07AB02, metoprolol, Mannitol may increase the excretion rate of Metoprolol which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CD01, metyrapone, Mannitol may increase the excretion rate of Metyrapone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BB03, aminopyrine, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Aminophenazone.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Parnaparin.]
[N05CD08, midazolam, Mannitol may increase the excretion rate of Midazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[G03XB01, mifepristone, The serum concentration of Mannitol can be increased when it is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Tinzaparin.]
[A06AA01, mineral oil, The risk or severity of adverse effects can be increased when Mannitol is combined with Mineral oil.]
[J05AH01, zanamivir, Mannitol may increase the excretion rate of Zanamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA03, valsartan, The risk or severity of adverse effects can be increased when Valsartan is combined with Mannitol.]
[D11AX01, minoxidil, The risk or severity of adverse effects can be increased when Minoxidil is combined with Mannitol.]
[L03AC01, aldesleukin, Mannitol may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BD01, amiodarone, The serum concentration of Mannitol can be increased when it is combined with Amiodarone.]
[N06AA09, amitriptyline, Mannitol may increase the excretion rate of Amitriptyline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AA01, morphine, The serum concentration of Mannitol can be increased when it is combined with Morphine.]
[A04AA05, palonosetron, Mannitol may increase the excretion rate of Palonosetron which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD06, moxalactam, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Latamoxef.]
[L04AB05, certolizumab pegol, Mannitol may increase the excretion rate of Certolizumab pegol which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BA01, ammonium chloride, Mannitol may increase the excretion rate of Ammonium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Mannitol.]
[L04AA06, mycophenolic acid, Mannitol may increase the excretion rate of Mycophenolic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Mannitol.]
[G04CA04, silodosin, The serum concentration of Silodosin can be increased when it is combined with Mannitol.]
[C07AA12, nadolol, Mannitol may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CA04, amoxicillin, Mannitol may increase the excretion rate of Amoxicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Mannitol.]
[N02AF02, nalbuphine, The therapeutic efficacy of Mannitol can be decreased when used in combination with Nalbuphine.]
[V03AB15, naloxone, Mannitol may increase the excretion rate of Naloxone which could result in a lower serum level and potentially a reduction in efficacy.]
[N07BB04, naltrexone, The therapeutic efficacy of Mannitol can be decreased when used in combination with Naltrexone.]
[N06BA01, amphetamine, Mannitol may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA12, naproxen, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Naproxen.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Mannitol is combined with Duloxetine.]
[N04BX01, tolcapone, Mannitol may increase the excretion rate of Tolcapone which could result in a lower serum level and potentially a reduction in efficacy.]
[S03AA01, neomycin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Neomycin.]
[N01AH06, remifentanil, The therapeutic efficacy of Mannitol can be decreased when used in combination with Remifentanil.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Mannitol is combined with Levosimendan.]
[B01AC17, tirofiban, Mannitol may increase the excretion rate of Tirofiban which could result in a lower serum level and potentially a reduction in efficacy.]
[J02AA01, amphotericin B, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Amphotericin B.]
[S01AA19, ampicillin, Mannitol may increase the excretion rate of Ampicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AX16, plerixafor, Mannitol may increase the excretion rate of Plerixafor which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA23, netilmicin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Netilmicin.]
[N06AX23, desvenlafaxine, Mannitol may increase the excretion rate of Desvenlafaxine which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA07, telmisartan, The risk or severity of adverse effects can be increased when Mannitol is combined with Telmisartan.]
[J05AB11, valacyclovir, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Valaciclovir.]
[C01CE01, inamrinone, Mannitol may increase the excretion rate of Amrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF02, nialamide, Nialamide may increase the orthostatic hypotensive activities of Mannitol.]
[C08CA04, nicardipine, The risk or severity of adverse effects can be increased when Nicardipine is combined with Mannitol.]
[C08CA05, nifedipine, Mannitol may increase the excretion rate of Nifedipine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA17, niflumic acid, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Niflumic acid.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Mannitol is combined with Amyl Nitrite.]
[C08CA06, nimodipine, The risk or severity of adverse effects can be increased when Nimodipine is combined with Mannitol.]
[C08CA07, nisoldipine, Mannitol may increase the excretion rate of Nisoldipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA08, nitrendipine, The risk or severity of adverse effects can be increased when Mannitol is combined with Nitrendipine.]
[R07AX01, nitric oxide, Mannitol may increase the excretion rate of Nitric Oxide which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XE01, nitrofurantoin, Mannitol may increase the excretion rate of Nitrofurantoin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF03, zaleplon, Mannitol may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC05, pramipexole, Mannitol may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DD01, nitroprusside, Mannitol may increase the excretion rate of Nitroprusside which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA03, norepinephrine, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Mannitol.]
[C02KX01, bosentan, Mannitol may increase the hypotensive activities of Bosentan.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Mannitol.]
[A16AX07, sapropterin, The serum concentration of Mannitol can be increased when it is combined with Sapropterin.]
[G02CA02, nylidrin, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Nylidrin.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Reviparin.]
[N02AA02, opium, Mannitol may increase the excretion rate of Opium which could result in a lower serum level and potentially a reduction in efficacy.]
[G04CA02, tamsulosin, Mannitol may increase the excretion rate of Tamsulosin which could result in a lower serum level and potentially a reduction in efficacy.]
[M05BA08, zoledronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Mannitol is combined with Zoledronic acid.]
[J01CF04, oxacillin, Mannitol may increase the excretion rate of Oxacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA04, oxazepam, Mannitol may increase the excretion rate of Oxazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Mannitol is combined with Oxprenolol.]
[N02AA05, oxycodone, The therapeutic efficacy of Mannitol can be decreased when used in combination with Oxycodone.]
[N02AA11, oxymorphone, The therapeutic efficacy of Mannitol can be decreased when used in combination with Oxymorphone.]
[S01BC02, oxyphenbutazone, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Oxyphenbutazone.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Danaparoid.]
[N02AX06, tapentadol, The therapeutic efficacy of Mannitol can be decreased when used in combination with Tapentadol.]
[J04AB30, capreomycin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Capreomycin.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Mannitol is combined with Papaverine.]
[C02KC01, pargyline, Pargyline may increase the orthostatic hypotensive activities of Mannitol.]
[A07AA06, paromomycin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Paromomycin.]
[G04BD11, fesoterodine, Mannitol may increase the excretion rate of Fesoterodine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA23, penbutolol, Mannitol may increase the excretion rate of Penbutolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AG03, penfluridol, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Penfluridol.]
[J01CE09, penicillin G procaine, Mannitol may increase the excretion rate of Procaine benzylpenicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AD01, pentazocine, The therapeutic efficacy of Mannitol can be decreased when used in combination with Pentazocine.]
[N05CA01, pentobarbital, Pentobarbital may increase the hypotensive activities of Mannitol.]
[L01XX08, pentostatin, Mannitol may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Mannitol may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[C08EX02, perhexiline, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Perhexiline.]
[N02AD02, phenazocine, The therapeutic efficacy of Mannitol can be decreased when used in combination with Phenazocine.]
[G04BX06, phenazopyridine, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Phenazopyridine.]
[N06AF03, phenelzine, Phenelzine may increase the orthostatic hypotensive activities of Mannitol.]
[N03AA02, phenobarbital, Phenobarbital may increase the hypotensive activities of Mannitol.]
[A06AB01, oxyphenisatin, The risk or severity of adverse effects can be increased when Mannitol is combined with Oxyphenisatin.]
[N01AH04, phenoperidine, The therapeutic efficacy of Mannitol can be decreased when used in combination with Phenoperidine.]
[C04AX02, phenoxybenzamine, The risk or severity of adverse effects can be increased when Mannitol is combined with Phenoxybenzamine.]
[V03AB36, phentolamine, Mannitol may increase the excretion rate of Phentolamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA01, phenylbutazone, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Phenylbutazone.]
[S01AE05, levofloxacin, Mannitol may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[B02BA01, vitamin K1, Mannitol may increase the excretion rate of Phylloquinone which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AB12, cidofovir, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cidofovir.]
[C08CX01, mibefradil, The serum concentration of Mannitol can be increased when it is combined with Mibefradil.]
[C07AA03, pindolol, Mannitol may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CA12, piperacillin, Mannitol may increase the excretion rate of Piperacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE01, saquinavir, The serum concentration of Mannitol can be increased when it is combined with Saquinavir.]
[N06BX03, piracetam, Mannitol may increase the excretion rate of Piracetam which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA02, eprosartan, The risk or severity of adverse effects can be increased when Mannitol is combined with Eprosartan.]
[N02AC03, pirinitramide, The therapeutic efficacy of Mannitol can be decreased when used in combination with Piritramide.]
[S01BC06, piroxicam, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Piroxicam.]
[J01DD16, cefditoren, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefditoren.]
[C09CA04, irbesartan, The risk or severity of adverse effects can be increased when Mannitol is combined with Irbesartan.]
[A10BG02, rosiglitazone, Mannitol may increase the excretion rate of Rosiglitazone which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AD15, polyethylene glycols, The risk or severity of adverse effects can be increased when Mannitol is combined with Polyethylene glycol.]
[S03AA03, polymyxin B, The risk or severity of adverse effects can be increased when Mannitol is combined with Polymyxin B.]
[C03AA05, polythiazide, The risk or severity of adverse effects can be increased when Polythiazide is combined with Mannitol.]
[J05AE03, ritonavir, The serum concentration of Mannitol can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, Mannitol may increase the excretion rate of Saxagliptin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Mannitol.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Mannitol.]
[C07AB01, practolol, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Practolol.]
[C02CA01, prazosin, The risk or severity of adverse effects can be increased when Prazosin is combined with Mannitol.]
[H02AB07, prednisone, Mannitol may increase the excretion rate of Prednisone which could result in a lower serum level and potentially a reduction in efficacy.]
[C01DX02, prenylamine, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Prenylamine.]
[N03AA03, primidone, Primidone may increase the hypotensive activities of Mannitol.]
[M04AB01, probenecid, Mannitol may increase the excretion rate of Probenecid which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BA02, procainamide, Mannitol may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, Procaine may increase the orthostatic hypotensive activities of Mannitol.]
[L01XB01, procarbazine, Procarbazine may increase the orthostatic hypotensive activities of Mannitol.]
[C10AB05, fenofibrate, Mannitol may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AD02, promethazine, Mannitol may increase the excretion rate of Promethazine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BC03, propafenone, The serum concentration of Mannitol can be increased when it is combined with Propafenone.]
[A03AB05, propantheline, Mannitol may increase the excretion rate of Propantheline which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AX26, fexofenadine, The serum concentration of Fexofenadine can be increased when it is combined with Mannitol.]
[L01XH02, romidepsin, The serum concentration of Romidepsin can be increased when it is combined with Mannitol.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Mannitol is combined with Propofol.]
[N02AC04, propoxyphene, The therapeutic efficacy of Mannitol can be decreased when used in combination with Dextropropoxyphene.]
[C07AA05, propranolol, Mannitol may increase the excretion rate of Propranolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CC04, rizatriptan, Mannitol may increase the excretion rate of Rizatriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC09, epoprostenol, Mannitol may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX12, aripiprazole, Aripiprazole may increase the hypotensive activities of Mannitol.]
[N07XX07, dalfampridine, Mannitol may increase the excretion rate of Dalfampridine which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CC01, pyrantel, Mannitol may increase the excretion rate of Pyrantel which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK01, pyrazinamide, Mannitol may increase the excretion rate of Pyrazinamide which could result in a lower serum level and potentially a reduction in efficacy.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Mannitol.]
[C01BA01, quinidine, Mannitol may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[P01BC01, quinine, The serum concentration of Mannitol can be increased when it is combined with Quinine.]
[A02BA02, ranitidine, Mannitol may increase the excretion rate of Ranitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA01, rescinnamine, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Rescinnamine.]
[C02AA02, reserpine, The serum concentration of Mannitol can be increased when it is combined with Reserpine.]
[J05AP01, ribavirin, Mannitol may increase the excretion rate of Ribavirin which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA05, salicylamide, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Salicylic acid.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Mannitol.]
[N04BD01, selegiline, Selegiline may increase the orthostatic hypotensive activities of Mannitol.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Mannitol is combined with Obinutuzumab.]
[J01GB08, sisomicin, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Sisomicin.]
[A12CD01, sodium fluoride, Mannitol may increase the excretion rate of Sodium fluoride which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA07, sotalol, The risk or severity of adverse effects can be increased when Sotalol is combined with Mannitol.]
[L01CD04, cabazitaxel, The serum concentration of Cabazitaxel can be increased when it is combined with Mannitol.]
[C03DA01, spironolactone, The risk or severity of adverse effects can be increased when Spironolactone is combined with Mannitol.]
